Patient-centered simulations to assess the usefulness of the 70-gene signature for adjuvant chemotherapy administration in early-stage breast cancer

@article{Caruana2018PatientcenteredST,
  title={Patient-centered simulations to assess the usefulness of the 70-gene signature for adjuvant chemotherapy administration in early-stage breast cancer},
  author={Emmanuel Caruana and Yohann Foucher and Philippe Tessier and Jean-S{\'e}bastien Fr{\'e}nel and Jean-Marc Classe and Etienne Dantan},
  journal={Breast Cancer Research and Treatment},
  year={2018},
  volume={174},
  pages={537-542}
}
PurposeFrom the MINDACT trial, Cardoso et al. did not demonstrate a significant efficacy for adjuvant chemotherapy (CT) for women with early-stage breast cancer presenting high clinical and low genomic risks. Our objective was to assess the usefulness of the 70-gene signature in this population by using an alternative endpoint: the number of Quality-Adjusted Life-Years (QALYs), i.e., a synthetic measure of quantity and quality of life.MethodsBased on the results of the MINDACT trial, we… CONTINUE READING

Tables and Topics from this paper.

References

Publications referenced by this paper.
SHOWING 1-10 OF 33 REFERENCES

Interpretation of the Results of the MINDACT Study and Consequent Recommendations in the Updated ASCO Clinical Practice Guideline.

  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2017
VIEW 11 EXCERPTS
HIGHLY INFLUENTIAL

[70-Gene signature as an aid to treatment decisions in early-stage breast cancer].

  • Nederlands tijdschrift voor geneeskunde
  • 2017
VIEW 10 EXCERPTS
HIGHLY INFLUENTIAL

Toward patient-centered drug development in oncology.

  • The New England journal of medicine
  • 2013
VIEW 12 EXCERPTS
HIGHLY INFLUENTIAL